Limitations, agreements, and source contact

An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma · Source last updated 2016-03-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

GT60

restrictive Agreement

true

point Of Contact

email

renaud.buffet@innate-pharma.fr

organization

Innate Pharma

phone

+33430303032

title

Dr Renaud Buffet Senior Director, Clinical Development and Translational Research

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice